海思科医药集团股份有限公司成立于2000年，是一家集新药研发、生产制造、 销售等业务于一体的多元化、专业化医药集团上市公司，在麻醉镇痛，肿瘤、营 养，消化肝病等领域占据重要的市场地位。 海思科以研发为核心竞争力，研发创新能力位列国内企业第一梯队。聚焦小分 子创新药研发领域，海思科针对靶点开发具有国际竞争力的创新药，以患者为中 心深度布局产品管线，围绕围手术期用药（如麻醉、镇痛、抗凝）、肿瘤用药（如 PROTAC、肿瘤免疫、分子靶向）、代谢相关疾病（如NASH、糖尿病）、自身免 疫性疾病（如炎性肠病、银屑病）及其他疾病（如哮喘、COPD）等领域构建创新 药研究技术平台。 2024年，历经10年，海思科第二款1.1类创新第三代中枢神经系统钙离子通道调 节剂成功上市，是自主研发且具有全球自主知识产权的1类创新药，上市后第一适应 症填补了国内在成人糖尿病性周围神经病理性疼痛治疗领域的空白。后续海思科将以每年上市一个创新药的速度，为临床提供更多更好的治疗选择。 Haisco Pharmaceutical Group Co., Ltd. was established in 2000. It is a diversified,  professional pharmaceutical group listed company integrating R&D, manufacturing  and sales of new drugs. The Company's R&D strength ranks among the top in the  chemical pharmaceutical industry.  Haisco has strong technical strength, the R&D center has various scientific  research personnel who are more than 700 in total, including numbers of PhDs and  Masters. Currently, the R&D center has initiated 65 new projects in the specialized  fields of innovative drugs and high-end generic drugs, involving multiple disease  fields such as anesthesia and analgesia, diabetes mellitus and complications,  tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and  respiratory diseases. Currently, there are a total of nine Category 1 new drugs under  development.

地址：西藏山南市泽当镇三湘大道17号

No.17, Sanxiang Avenue, Zedang Town, Shannan City,

Xizang

电话：86-010-64712166